Browsing Tag
Stoke Therapeutics
2 posts
Stoke Therapeutics has enrolled its pivotal Dravet trial, but what must the August 3 call prove?
Stoke Therapeutics will discuss its second-quarter performance on August 3 after completing enrollment in the pivotal EMPEROR trial. Investors will be looking beyond quarterly revenue to assess spending, regulatory execution and preparations for a possible zorevunersen launch.
Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome
US biotech company Stoke Therapeutics has secured orphan drug designation for its lead product candidate – STK-001 from…